Hepalink shareholders approve governance changes, new director Pu Hong

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. held its 2025 First Extraordinary General Meeting (EGM) on December 16, 2025, where shareholders approved several key proposals. A total of 988,374,124 shares with voting rights, representing 67.36% of the company's total shares, were present.

A special resolution to abolish the supervisory committee and amend the articles of association passed with 99.9814% of votes for. Two ordinary resolutions also passed: one to amend internal corporate governance measures, with 98.1703% for; and another to elect Mr. Pu Hong as an independent non-executive director, receiving 99.9767% of votes for.

Following the EGM, Mr. Pu Hong was appointed as chairman of the nomination committee and a member of both the strategy and audit committees, effective December 16, 2025. The approved amendments to the articles and corporate governance measures also took effect on this date.